Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment
Standard of care HNSCC regimens with curative intent demand surgery, radiation, and chemotherapy - treatments that many patients cannot tolerate.
Immuno
Autologous versus allogeneic: how cell therapy development is changing in oncology
SLE and LN market expected to reach $5.9bn across 7MM by 2034
Sensei to ditch its lead candidate and cut workforce amidst strategic review
Teva to collaborate with Fosun Pharma for TEV-56278
EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
NICE approves GSK’s belantamab mafodotin for blood cancer
Antares Therapeutics gains $177m for cancer medicines development
